Why CVS Health Shares Are Rising

CVS Health Corp (NYSE: CVS) shares are trading higher by 2.43% to $74.06 Wednesday morning. Shares of healthcare stocks are trading higher in sympathy with Elevance Health, which reported better-than-expected second-quarter financial results and raised guidance.

CVS Health Corp (NYSE:CVS) shares are trading higher by 2.43% to $74.06 Wednesday morning. Shares of healthcare stocks are trading higher in sympathy with Elevance Health, which reported better-than-expected second-quarter financial results and raised guidance.

What Happened?

Elevance Health has announced adjusted second-quarter EPS of $9.04, reflecting a 13.4% year-over-year increase and surpassing the consensus estimate of $8.80. Furthermore, the company experienced a 13% growth in revenue, reaching $43.67 billion, exceeding the projected figure of $41.50 billion.

This increase can be attributed to premium rate increases in the Health Benefits business, higher premium revenue resulting from membership growth in Medicaid and Medicare, as well as the expansion of pharmacy product revenue through the acquisition of BioPlus in Q1 2023 and the growth of external pharmacy members served by CarelonRxRead More

According to data from Benzinga Pro, CVS has a 52-week high of $107.26 and a 52-week low of $66.34.

Total
0
Shares
Related Posts
Read More

Genetic Technologies Announced New Publication Highlights geneType’s ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company","GTG") is pleased to announce the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment. Highlights: • GeneType outperforms 5-year and remaining lifetime risk prediction compared to the commonly used clinical models Gail and IBISv7, respectively.

GENE